This lecture was supported by Grant Number 6H79FG000999-01M001 from SAMHSA. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of SAMHSA. 

About the speaker

A. John Rush, MD is Professor Emeritus, National University of Singapore, and Adjunct Professor of Psychiatry Duke School of Medicine, North Carolina. His research has focused on the development and testing of innovative treatments for mood disorders, including medications, brain stimulation, psychotherapeutic and disease management protocols. As author of over 800 peer-reviewed articles, book chapters, and books, his work has received international recognition with awards from many professional organizations, including the American Psychiatric Association, the American College of Psychiatrists, and the Society for Biological Psychiatry among other.  Thomson Reuters recognized Dr. Rush as one of the “World’s Most Influential Scientific Minds” in 2014. As CEO of Curbstone Consultant LLC., he currently provides research and organizational consultation to commercial, governmental, academic, and not for profit organizations, as well individual career mentoring.

Disclosure Statements

Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she has with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt, and if there will be discussion of any products, services, or off-label uses of product(s) during this presentation.

A. John Rush, MD, reports that he has consulted with Compass Inc.,Evecxia Therapeutics, Holmusk Technologies, ICON PLC, Johnson and Johnson, Liva Nova, MindStreet Inc, Neurocrine Biosciences, and Otsuka-US; has received speaking fees from Liva-Nova and Johnson and Johnson; has received royalties from  Wolters Kluwer Health, Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptoms and its derivatives); and has two US patents. The content of his presentation was reviewed to find and mitigate any conflicts of interest to ensure that the information presented is balanced and evidence-based and contains no logos, brand-names, promotion or advertisements.

Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months: Todd Peters, MD, Deepak Prabhakar, MD, Elizabeth Ryznar, MD, MSc, Louis Marino, MD, Ehsan Syed, MD, Devi Bhuyan, PsyD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Stacey Garnett, RN, MSN, Stephanie M. Robinson, MSN, RN, PMH-BC, NPD-BC, NE-BC , Heather Billings, RN, Lisa Illum, MLIS, MEd, and Jennifer Tornabene.